Screening for prostate cancer: current recommendationsShandra S Wilson
Department of Urologic Oncology, Anschutz Cancer Center, 1665 North Ursula, Aurora, CO 80010, USA
Urol Clin North Am 31:219-26. 2004
..It is hoped that prospective, randomized, long-term screening studies, such as the PLCO and ERSCP trials, will show improved survival using the admittedly imperfect PSA marker in prostate cancer screening...
- Controversies regarding screening for prostate cancer
E David Crawford
Department of Urologic Oncology, University of Colorado, Denver, CO 80010, USA
BJU Int 100:5-7. 2007
- Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial
Paul F Pinsky
Division of Cancer Prevention, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
BJU Int 99:775-9. 2007
..To determine patterns of repeat prostate biopsy in a cohort of men undergoing prostate cancer screening who have a negative initial biopsy...
- Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial
Gerald L Andriole
Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
J Natl Cancer Inst 97:433-8. 2005
..We describe the population enrolled in the PLCO trial, their baseline PSA and DRE screening results, and diagnostic follow-up results during the first year of follow-up...
- Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program
Al Baha Barqawi
Section of Urologic Oncology, University of Colorado Health Science Center School of Medicine, Denver, Colorado, USA
Urology 65:708-12. 2005
..To assess the effect of aging and body mass index (BMI) on both serum total prostate-specific antigen (tPSA) and complexed PSA (cPSA) from the results of the 2003 Prostate Cancer Awareness Week national screening database...
- Screening for prostate cancer
Shandra S Wilson
Department of Urologic Oncology, Anschutz Cancer Center, Denver, CO, USA
Clin Prostate Cancer 3:21-5. 2004
..These measures include prevention, screening, improved curative treatment, and the transformation of an acute lethal disease to a chronic, tolerable one. This summary focuses on the screening aspects of prostate cancer...
- Epidemiology of prostate cancer
E David Crawford
Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
Urology 62:3-12. 2003
..In contrast, mortality rates for men diagnosed with localized or regional disease increased gradually during most of the 1990s before decreasing slightly among white men and reaching plateaus among African Americans...
- Is a screening interval of every 4 years for prostate cancer acceptable?
E David Crawford
J Natl Cancer Inst 99:1279-80. 2007
- Screening for prostate cancer in 2006: PSA in the 21st century
Paul D Maroni
Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, USA
N C Med J 67:136-9. 2006
- Should routine screening for prostate-specific antigen be recommended?
Siam Oottamasathien
Division of Urology, Box c319, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
Arch Intern Med 163:661-2; discussion 666. 2003
- Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial
E David Crawford
Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, Washington, DC, USA
J Urol 175:1286-90; discussion 1290. 2006
..A large fraction of screened men have low (less than 2 ng/ml) initial PSA. The yield over time of positive PSA screens (ie more than 4 ng/ml) in these men has not been well characterized in large cohorts in the United States...
- Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)
Maha Hussain
University of Michigan, Ann Arbor, MI, USA
J Clin Oncol 24:3984-90. 2006
..2 ng/mL or less. CONCLUSION: A PSA of 4 ng/mL or less after 7 months of AD is a strong predictor of survival. This data should be used to tailor future trial design for D2 prostate cancer...
- Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial
Paul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethedsa, Maryland, USA
Urology 68:352-6. 2006
..Here we examine the relationship between prostate volume and PSA level in a large, geographically diverse sample of men undergoing prostate cancer screening...
- Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove
Abraham Morgentaler
J Urol 175:1572; author reply 1573-4. 2006
- Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer
Dominique S Michaud
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Res 66:4525-30. 2006
..At least seven common polymorphisms in genes of inflammatory cytokines IL-1B, IL-6, IL-8, and IL-10 do not seem to play a role in the risk of prostate cancer...
- Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia
James R Marshall
Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Cancer Epidemiol Biomarkers Prev 15:1479-84. 2006
..Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009...
- Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024
Gregory P Swanson
University of Texas Health Science Center, San Antonio, USA
J Urol 176:548-53; discussion 553. 2006
..The modest response rate indicates that better chemotherapy that improves local and systemic failure is necessary to improve the results. This study confirms the feasibility of a combined chemoradiotherapy approach...
- Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
Daniel P Petrylak
Columbia University, New York, NY 10032, USA
J Natl Cancer Inst 98:516-21. 2006
..We evaluated PSA changes as potential surrogate markers for survival by using data from a clinical trial...
- A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer
Thomas W Flaig
Department of Medicine, University of Colorado Health Sciences Center, Aurora, CO 80045 0511, USA
Cancer 107:266-74. 2006
..Preclinical data from prostate cancer cell lines suggested a synergistic effect of these therapies...
- Metastatic prostate cancer-does treatment of the primary tumor matter?
Gregory Swanson
Department of Radiation Oncology, University of Texas Health Science Center at San Antonio and Cancer Therapy and Research Center, San Antonio, Texas, 78229 3900, USA
J Urol 176:1292-8. 2006
..We reviewed the effect of treating the principal disease bulk on overall treatment outcome in patients with advanced and metastatic cancer. Specifically we evaluated the role of surgical tumor cytoreduction...
- Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial
Ian M Thompson
Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
JAMA 296:2329-35. 2006
..However, the optimal management of these patients after radical prostatectomy is unknown...
Multiple loci identified in a genome-wide association study of prostate cancerGilles Thomas
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
Nat Genet 40:310-5. 2008
..Our findings point to multiple loci with moderate effects associated with susceptibility to prostate cancer that, taken together, in the future may predict high risk in select individuals...
- Endogenous sex hormones and the risk of prostate cancer: a prospective study
Jocelyn M Weiss
Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, MD, USA
Int J Cancer 122:2345-50. 2008
..T:SHBG ratio was related to risk in this older population of men, but the significance of this ratio in steroidal biology is unclear. (c) 2008 Wiley-Liss, Inc...
- The current use and future trends of focal surgical therapy in the management of localized prostate cancer
Al B Barqawi
Urologic Oncology Department, School of Medicine, University of Colorado Health Science Center, Denver, CO, USA
Cancer J 13:313-7. 2007
..In addition, we will discuss future promising tools in MIT such as photodynamic therapy and the target focal therapy approach as a new trend for the treatment of organ-confined low-volume disease...
- Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
R Bruce Montgomery
University of Washington and Southwest Oncology Group Statistical Center, Seattle, Washington, USA
J Urol 178:1946-51; discussion 1951. 2007
..We evaluated the effect of body mass index on prostate specific antigen response, and progression-free and overall survival in men with androgen dependent or androgen independent metastatic prostate cancer...
- Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
M Scott Lucia
Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
J Natl Cancer Inst 99:1375-83. 2007
..We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size...
- IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Jocelyn M Weiss
Division of Cancer Epidemiology and Genetics, NCI NIH, Bethesda, MD, USA
Int J Cancer 121:2267-73. 2007
..11-7.08). In summary, our large prospective study showed no overall association between the insulin-like growth factor axis and prostate cancer risk, however, IGFmr was related to risk for aggressive prostate cancer in obese men...
- The association of time of day and serum testosterone concentration in a large screening population
E David Crawford
Surgery and Radiation Oncology, Section of Urologic Oncology, UCHSC, Aurora, CO, USA
BJU Int 100:509-13. 2007
....
- Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794
Gregory P Swanson
Department of Radiation Oncology and Urology, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
J Clin Oncol 25:2225-9. 2007
..In this analysis, we stratified patients as to their preradiation PSA levels and correlated it with outcomes such as PSA treatment failure, local recurrence, and distant failure, to serve as guidelines for future research...
- Prostate cancer in a man with multiple previous cancers
Thomas Flaig
University of Colorado, Health Sciences Center, Aurora, Colorado, USA
Oncology (Williston Park) 21:611-4. 2007
- Bone metabolism and new targets for intervention
Bulent Akduman
Department of Urology, School of Medicine, Zonguldak Karaelmas University, Zonguldak, Turkey
Curr Urol Rep 8:233-8. 2007
..In addition to traditional treatment approaches, targeted therapy is currently becoming more popular. Bone metabolism, metastatic processes of prostate cancer, and the targeting of treatment for advanced disease are discussed here...
- Prostate-specific antigen velocity and prostate cancer gleason grade and stage
Paul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer 109:1689-95. 2007
..The authors evaluated the relation between PSAV, biopsy Gleason score, and pathologic stage in men who were enrolled in a prostate cancer screening trial...
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)A Oliver Sartor
Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Cancer 112:2393-400. 2008
..This study was designed to examine antiandrogen withdrawal effects within the context of a large multi-institutional prospective trial...
- Controversies of androgen ablation therapy for metastatic prostate cancer
Shandra S Wilson
Department of Urologic Oncology, 1665 North Ursula, Aurora, CO 80010, USA
Curr Pharm Des 12:799-805. 2006
....
- A prospective study of lycopene and tomato product intake and risk of prostate cancer
Victoria A Kirsh
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, MD 20892, USA
Cancer Epidemiol Biomarkers Prev 15:92-8. 2006
..Evidence for protective associations in subjects with a family history of prostate cancer requires further corroboration...
- Artificial neural networks for predictive modeling in prostate cancer
Eduard J Gamito
University of Colorado Health Sciences Center, C 314, 200 East 9th Avenue, Denver, CO 80262, USA
Curr Oncol Rep 6:216-21. 2004
..This article provides an overview of the theoretical basis of ANNs, how they function, their strengths and limitations, and examples of how ANNs have been used to develop predictive models for the management of prostate cancer...
- High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade
Zinelabidine Abouelfadel
Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
Clin Prostate Cancer 1:115-7. 2002
..Continued screening for prostate cancer is resulting in the diagnosis of more unfavorable cancers...
- Ten-year survival in patients with metastatic prostate cancer
Catherine M Tangen
The Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Clin Prostate Cancer 2:41-5. 2003
..Although statistically significant baseline characteristics were identified in this clinical trial, they did not accurately predict the survival interval to which a patient belonged...
- Herbal and vitamin supplement use in a prostate cancer screening population
Albaha Barqawi
Section of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Urology 63:288-92. 2004
..Additional investigation is warranted into the reason some men are not receiving standard prescription medications for LUTS and whether reliance on alternative treatments is playing a role in this phenomenon...
- The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer
Marileila Varella-Garcia
University of Colorado Comprehensive Cancer Center, UCHSC, Denver CO, USA
Urol Oncol 22:16-9. 2004
....
- Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks
E David Crawford
Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
Urology 62:13-9. 2003
....
- Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy
Al Baha Barqawi
Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Urology 62:872-6. 2003
..The efficacy appears to be greater in patients who can achieve a PSA nadir of 0.1 ng/mL or less after the start of treatment...
- Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
L Michael Glode
Oncology Urology Department, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Cancer 98:1643-8. 2003
....
- Early versus late hormonal therapy: debating the issues
E David Crawford
Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center, Denver, Colorado 80010, USA
Urology 61:8-13. 2003
..Thus, accumulating evidence provides a rationale for continued investigation into the use of early hormonal therapy in selected patients...
- Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning
Tracy R Glass
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
J Urol 169:164-9. 2003
..Risk stratification is helpful for designing clinical trials and individual treatment, and it should be incorporated into future reports of outcomes of patients with metastatic disease...
- Predicting the outcome of prostate biopsy in a racially diverse population: a prospective study
Christopher R Porter
Department of Urology, State University of New York, Stony Brook, New York, USA
Urology 60:831-5. 2002
..76) were constructed from a contemporary, prospective database. Such models may be useful to patients and physicians alike when assessing the diagnostic strategies available to detect prostate cancer...
- SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study
Catherine E Klein
University of Colorado, Denver, Colorado, USA
Prostate 52:264-8. 2002
..Topotecan is a new topoisomerase-1 inhibitor whose early investigation suggested possible activity in hormone-refractory prostate cancer...
- Biochemical recurrence and survival prediction models for the management of clinically localized prostate cancer
Ashuthosh Tewari
Institute for Clinical Research at the Veterans Affairs, Medical Center Vattikuti Urology Institute and Josephine Ford Cancer Center, Henry Ford Health System, Detroit, MI, USA
Clin Prostate Cancer 2:220-7. 2004
....
- Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
Ian M Thompson
Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
N Engl J Med 350:2239-46. 2004
..1 to 4.0 ng per milliliter. CONCLUSIONS: Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less--levels generally thought to be in the normal range...
- A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer
E David Crawford
Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
J Urol 175:533-6. 2006
..The safety, efficacy and pharmacokinetics of LA-2585, a new 6-month subcutaneous depot of leuprolide acetate (Atrix Laboratories, Fort Collins, Colorado) were investigated in patients with prostate cancer...
- Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111
Maha Hussain
University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
J Clin Oncol 23:8724-9. 2005
..The epothilones are a new class of tubulin-polymerizing agents with activity in taxane-sensitive and resistant tumor models. We evaluated ixabepilone (BMS-247550) in patients with metastatic hormone-refractory prostate cancer (HRPC)...
- Minimally invasive surgery in prostate cancer: current and future perspectives
Bulent Akduman
University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, Aurora, Colorado 80010, USA
Cancer J 11:355-61. 2005
..In this review we critically discuss the current knowledge and future perspectives of minimally invasive treatment in prostate cancer...
- Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy
E David Crawford
Radiation Oncology, Department of Pathology, University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO 80045, USA
BJU Int 96:999-1004. 2005
....
- Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer
Ashutosh Tewari
Josephine Ford Cancer Center and Vattikuti Urology Institute, Henry Ford Health, System, Detroit, MI, USA
BJU Int 96:29-33. 2005
..The PSA doubling time after recurrence may also be important, leading to the increased mortality of AA men with prostate cancer...
- Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting
Christopher R Porter
Section of Urology and Renal Transplantation, Virginia Mason Medical Center, Seattle, Washington 98111, USA
Urology 65:937-41. 2005
..To develop a model capable of predicting prostate biopsy outcomes in a large screening population, with independent validation in the referral setting...
- Preventing and treating the complications of hormone therapy
Ravi J Kumar
Urologic Oncology, University of Colorado Health Sciences Center, 4200 East 9th Avenue C 319, Denver, CO 80262, USA
Curr Urol Rep 6:217-23. 2005
....
- PSA testing: what is the use?
E David Crawford
University of Colorado, Denver, CO 80262, USA
Lancet 365:1447-9. 2005
- Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894
Tomasz M Beer
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
J Urol 172:2213-7. 2004
....
- Intermediate- to high-risk prostate cancer patient treated with radiation therapy
E David Crawford
University of Colorado Health Sciences Center, Denver, USA
Oncology (Williston Park) 18:1105-10. 2004
- The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
Ali Ziada
UCHSC, 4200 E 9th Ave C 319, Denver, CO, USA
Prostate 60:332-7. 2004
..To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin) in the treatment of advanced hormone-refractory prostate cancer (HRPC)...
- Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models
Priya N Werahera
Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Hum Pathol 35:798-807. 2004
..Moreover, our 3-dimensional computer modeling system improves upon other systems: It is more than a simple extension of the planimetric technique, and it is able to demarcate clearly the boundaries of Gleason grades just 1 grade apart...
- A 72-year-old man with prostate cancer
E David Crawford
University of Colorado Health Sciences Center, Denver, USA
Oncology (Williston Park) 16:1014-6, 1119-21. 2002
